Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.